Stockreport

Merck's Priority Review Cancer Drug Adds To Undervalued Growth Story [Yahoo! Finance]

DAIICHI SANKYO S/ADR  (DSNKY) 
PDF U.S. FDA accepts and grants Priority Review for the Biologics License Application for ifinatamab deruxtecan. The application covers treatment of adult patients with e [Read more]